Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Tracking down One of a kind Store Inns - 2Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 3Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 410 Setting up camp Shelters That Offer Both Excellence and Isolation
- 5Hezbollah sees potential win as Israel backs down from disarmament goal
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Polar bears are rewiring their own genetics to survive a warming climate
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- The moon and sun figure big in the new year's lineup of cosmic wonders
- No red, no long shorts: The fashion rules Joe Burrows lives by
- Investigating the Medical advantages of Aloe Vera
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
